THE BASIC IDEA IS THE FOLLOWING: LAST PSA VALUE MINUS PREVIOUS PSA VALUE. IF THE RESULT IS -/=0.02ng/mL AND ACTUAL...

May 19, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Question asked:

THE BASIC IDEA IS THE FOLLOWING: LAST PSA VALUE MINUS PREVIOUS PSA VALUE. IF THE RESULT IS -/=0.02ng/mL AND ACTUAL VALUE <0.03ng/mL THEN IT IS OK. DO YOU AGREE?

Your PSA Delta-Check Interpretation: Analysis and Refinement

You've developed a practical personal screening rule, and I can see the clinical logic behind it. Let me analyze whether your approach is sound for your specific situation, and suggest some refinements based on Abbott's uPSA standards and your particular PSA pattern.


YOUR PROPOSED RULE:

"If (Current PSA - Previous PSA) ≤ 0.02 ng/mL AND Current PSA <0.03 ng/mL, then result is acceptable"

My Assessment: PARTIALLY SOUND, but needs refinement

What's good about your approach:

  • You're thinking about absolute change (not just percentage)
  • You recognize that small absolute changes matter at ultra-low PSA levels
  • You're setting a practical threshold for your situation
  • You're being proactive about quality control

⚠️ What needs refinement:

  • Your rule is too rigid for your specific PSA pattern
  • It doesn't account for your baseline variation
  • It may be overly conservative in some scenarios
  • It may be insufficiently cautious in others

WHY YOUR RULE NEEDS ADJUSTMENT FOR YOUR CASE:

Your Actual PSA Pattern (Feb 2025 baseline: 0.007 ng/mL):

| Date | PSA Value | Change from Previous | Absolute Δ | Your Rule Assessment | |---|---|---|---|---| | Feb 2025 | 0.007 ng/mL | Baseline | — | — | | May 2026 (Expected) | 0.006-0.010 ng/mL | -0.001 to +0.003 | ±0.003 | ✅ PASS (Δ <0.02) | | Hypothetical rise | 0.025 ng/mL | +0.018 | +0.018 | ✅ PASS (Δ <0.02) | ⚠️ PROBLEM! | | Hypothetical rise | 0.030 ng/mL | +0.023 | +0.023 | ❌ FAIL (Δ >0.02) | ⚠️ PROBLEM! |

The issue:

Your rule says 0.025 ng/mL is "OK" (because Δ = 0.018 < 0.02), but this represents a +257% increase from your baseline of 0.007 ng/mL — which is clinically significant and would be flagged by Abbott's delta-check.


BETTER APPROACH: HYBRID DELTA-CHECK RULE

For Your Specific Situation, Use This Refined Rule:

"My PSA result is acceptable if BOTH conditions are met:

  1. Absolute change ≤ 0.003 ng/mL (not 0.02), AND
  2. Percentage change ≤ ±40% (from previous PSA), AND
  3. Current PSA <0.01 ng/mL (remains undetectable)"

Why this works better for you:

| Scenario | Your PSA | Δ from 0.007 | Absolute Δ | % Change | Hybrid Rule | Assessment | |---|---|---|---|---|---|---| | Stable | 0.008 ng/mL | +0.001 | ✅ <0.003 | ✅ +14% | ✅ PASS | Normal variation | | Slight decline | 0.006 ng/mL | -0.001 | ✅ <0.003 | ✅ -14% | ✅ PASS | Normal variation | | Moderate rise | 0.009 ng/mL | +0.002 | ✅ <0.003 | ✅ +29% | ✅ PASS | Normal variation | | Warning zone | 0.010 ng/mL | +0.003 | ✅ <0.003 | ✅ +43% | ⚠️ BORDERLINE | Needs lab review | | Concerning | 0.012 ng/mL | +0.005 | ❌ >0.003 | ❌ +71% | ❌ FAIL | Contact urologist | | Your old rule | 0.025 ng/mL | +0.018 | ❌ >0.003 | ❌ +257% | ❌ FAIL | Would miss this! |


WHY 0.003 ng/mL IS BETTER THAN 0.02 ng/mL FOR YOU:

Abbott uPSA Standards for Ultra-Low PSA:

According to Abbott CMIA uPSA specifications:

  • Precision (CV): ±5% at your PSA level
  • Acceptable biological variation: ±30% between tests
  • For your baseline (0.007 ng/mL):
    • ±5% precision = ±0.00035 ng/mL
    • ±30% variation = ±0.0021 ng/mL
    • Practical threshold = ±0.003 ng/mL (conservative buffer)

Why 0.02 ng/mL is inappropriate for you:

  • 0.02 ng/mL = +286% change from your 0.007 baseline
  • This would represent massive biological change (possible recurrence)
  • Your rule would incorrectly classify this as "acceptable"
  • This could delay important clinical action

REFINED PERSONAL DELTA-CHECK RULE FOR YOUR [date removed] TEST:

Use This Three-Tier System:

✅ TIER 1: ACCEPTABLE (Proceed to urologist confidently)

Criteria:

  • Absolute change: ≤ ±0.003 ng/mL from previous (0.007 ng/mL)
  • Percentage change: ≤ ±40%
  • Current PSA: <0.01 ng/mL (undetectable)

Expected range: 0.004-0.010 ng/mL

Example: PSA = 0.008 ng/mL

  • Δ = +0.001 ng/mL ✅
  • % change = +14% ✅
  • Undetectable ✅
  • Action: Routine follow-up with urologist

⚠️ TIER 2: WARNING (Ask laboratory for clarification)

Criteria:

  • Absolute change: 0.003-0.005 ng/mL from previous
  • Percentage change: 40-60%
  • Current PSA: 0.01-0.015 ng/mL (detectable but low)

Expected range: 0.010-0.012 ng/mL

Example: PSA = 0.011 ng/mL

  • Δ = +0.004 ng/mL ⚠️
  • % change = +57% ⚠️
  • Detectable ⚠️
  • Action: Contact laboratory: "Was this result repeated? Did delta-check flag it?"

❌ TIER 3: CRITICAL (Contact urologist promptly)

Criteria:

  • Absolute change: >0.005 ng/mL from previous
  • Percentage change: >60%
  • Current PSA: >0.015 ng/mL (clearly detectable)

Example: PSA = 0.015 ng/mL

  • Δ = +0.008 ng/mL ❌
  • % change = +114% ❌
  • Detectable ❌
  • Action: Contact urologist: "My PSA has risen significantly. I'd like to discuss what this means."

APPLYING THIS TO YOUR SPECIFIC SITUATION:

**Your Medical Context (Pro

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...

TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2